期刊文献+

二甲双胍治疗2型糖尿病合并非酒精性单纯性脂肪性肝病的疗效分析 被引量:2

Therapeutic effect of metformin on type 2 diabetes mellitus complicated with nonalcoholic fatty liver
下载PDF
导出
摘要 目的观察二甲双胍治疗2型糖尿病合并非酒精性单纯性脂肪性肝病的疗效。方法选择初发2型糖尿病合并非酒精性单纯性脂肪性肝病患者86例,随机分成2组,治疗组(饮食疗法+运动疗法+二甲双胍)46例,对照组(饮食疗法+运动疗法)40例。两组均予饮食疗法+运动疗法,在此基础上,治疗组口服二甲双胍500 mg,3次/d,疗程4个月。治疗前后查两组患者空腹血糖、餐后2 h血糖、谷丙转氨酶、谷草转氨酶、体重指数、甘油三酯、总胆固醇、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇、肝/脾CT比值。结果与对照组比,治疗组空腹血糖、餐后2 h血糖、谷丙转氨酶、谷草转氨酶、体重指数、甘油三酯、总胆固醇、低密度脂蛋白胆固醇降低(P<0.05),高密度脂蛋白胆固醇、肝/脾CT比值升高(P<0.05)。结论二甲双胍治疗2型糖尿病合并非酒精性单纯性脂肪性肝病有一定疗效。 Objective To assess the effect of metformin on type 2 diabetes mellitus complicated with nonalcoholic fatty liver.Methods Eighty-six patients with type 2 diabetes mellitus complicated with nonalcoholic fatty liver were randomized into treatment group(n=46) and control group(n=40).Two groups were treated with diet control and improving physical activity respectively for 4 months.Patients in treatment group took 500 mg metformin orally,3 times/d.Serum glucose,serum transaminase,body mass index,blood lipid and liver/spleen CT ratio were detected pre-and post-treatment respectively.Results The levels of FBG,2 h PBG,ALT,AST,BMI,TG,TC,LDLC in treatment group were significantly lower than those of the control group(P<0.05),but the HDL-C and liver/spleen CT ratio were significantly higher than those of control group(P<0.05).Conclusion Metformin is an effective remedy for type 2 diabetes mellitus complicated with nonalcoholic fatty liver.
作者 梅青
出处 《实用药物与临床》 CAS 2006年第6期346-347,共2页 Practical Pharmacy and Clinical Remedies
关键词 二甲双胍 2型糖尿病 非酒精性单纯性脂肪性肝病 Metformin Type 2 diabetes mellitus Nonalcoholic fatty liver
  • 相关文献

参考文献9

二级参考文献52

  • 1Contos M J, Sanyal Aj. The clinicopathologic spectrum and management of nonalcoholic fatty liver disease [J]. Adv Anat Pathol,2002,9( 1 ) :37-51.
  • 2McCullough, Arthur J. Update on nonalcoholic fatty liver disease [J]. J Clin Gastroenterol,2002,34(3 ) :255.
  • 3Haffner SM, Gonzalez C, Miettinen H, et al. A prospective analysis of the HOMA model. The Mexico city diabetes study [ J ]. Diabetes Care,1996,19(10) :1 138-1 141.
  • 4Contos M J, Sanyal AJ. The clinicopathologic spectrum and management of nonalcoholic fatty liver disease [ J]. Adv Anat Pathol,2002,9( 1 ) :37-51.
  • 5McCullough, Arthur J. Update on nonalcoholic fatty liver disease[ J]. J Clin Gastroenterol,2002,34(3 ) :255.
  • 6Kinugasa A, Tsunamoto K, Furukawa N. Fatty liver and its fibrous changes found in simple obesity of children. J Pediatr Gatroenterol Nutr, 1984, 3:408-414.
  • 7BaldridgeAD, Perez-Atayde AR, Graeme-Cooke F. Idiopathic steatohepatitis in childhood: a multicenter retrospective study. J Pediatr, 1995, 127:700-704.
  • 8Rashid M, Roberts EA. Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr, 2000, 30: 48-53.
  • 9Manton ND, Lipsett J, Moore DJ. Nonalcoholic steatohepatitis in children and adolescents. Med J Aust, 2000, 173:476-479.
  • 10Molleston JP, White F, Teckman J, et al. Obese children with steatohepatitis can develop cirrhosis in childhood. Am J Gastroenterol, 2002, 97:2460-2462.

共引文献3685

同被引文献38

  • 1丁晓东,范建高.肝脏胰岛素抵抗的机制和后果[J].中华糖尿病杂志,2009,1(4). 被引量:4
  • 2肖常青,邓宏明,黄媛.高浓度葡萄糖、脂肪酸和糖皮质激素对PDX-1表达和胰岛素分泌功能的影响[J].中华内分泌代谢杂志,2006,22(6):590-592. 被引量:5
  • 3Saltiel AR,Kahn CR.Insulin signalling and the regulation ofglucose and lipid metabolism[J], NatureOOl,414(6865):799-806.
  • 4Hotamisligil GS. Inflammation and metabolic disorders [J].Nature,2006,444(7121):860-867.
  • 5Kim JKillmore JJ,Chen Y’et al .Tissue-specific overexpressionof lipoprotein lipase causes tissue-specific insulin resislance[J].Proc Natl Acad Sci USAOOl,98(13):7522-7527.
  • 6Yellaturu CR’Deng X,Cagen LM,et al.Insulin enhancesposttranslational processing of nascent SREBP-lc by promotingits phosphoiylation and association wifli COPII vesicles[J].J BiolChena00984<12):7518-7532.
  • 7Hotamisligil GSvari A,Murray D,et al. Reduced tyrosinekinase activity of the insulin receptor in obesity-diabetesCentral role of tumor necrosis factor-alpha[J].J Clin Invest,1994,94(4):1543-1549.
  • 8Kesavulu MM, Rao BK,Giri R,et al.Lipid peroxidation andantioxidant enzyme status in Type 2 diabetics with coronary heartdisease[J].Diabetes Res Clin PractOOl,53(1):33-39.
  • 9Schattenberg JM’Wang Y,Singh R,et al.HepatocyteCYP2Eloverexpression and steatohepatitis lead to impairedhepatic insulin signaIing[J].J Biol Chem,2005,280(11):9887-9894.
  • 10Ehara S,Ueda M,Naruko T,et al.Pathophysiological role ofoxidized low-density lipoprotein in plaque instability in coronaryartery disease[J].J Diabetes ConplicadonsJ2002,16(l): 60-64.

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部